Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Dan Turner,Frank M. Ruemmele,Esther Orlanski-Meyer,Anne M. Griffiths,Javier Martín de Carpi,Jiri Bronsky,Gábor Veres,Marina Aloi,Caterina Strisciuglio,Christian Braegger,Amit Assa,Claudio Romano,Seamus Hussey,Michael Stanton,Mikko P. Pakarinen,Lissy de Ridder,Konstantinos H. Katsanos,Nicholas M. Croft,Víctor Manuel Navas-López,David C. Wilson,Sally Lawrence,Richard K. Russell +21 more
Reads0
Chats0
TLDR
These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.Abstract:
Background:The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with ∼20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through dread more
Citations
More filters
Journal ArticleDOI
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
Jeffrey S. Hyams,Sonia Davis Thomas,Sonia Davis Thomas,Nathan Gotman,Yael Haberman,Yael Haberman,Rebekah Karns,Melanie Schirmer,Melanie Schirmer,Angela Mo,David R. Mack,Brendan M. Boyle,Anne M. Griffiths,Neal S. Leleiko,Cary G. Sauer,David J. Keljo,James Markowitz,Susan S. Baker,Joel R. Rosh,Robert N. Baldassano,Ashish S. Patel,Marian Pfefferkorn,Anthony Otley,Melvin B. Heyman,Joshua D. Noe,Maria Oliva-Hemker,Paul A. Rufo,Jennifer A. Strople,David Ziring,Stephen L. Guthery,Boris Sudel,Keith J. Benkov,Prateek Wali,Dedrick E. Moulton,Jonathan Evans,Michael D. Kappelman,M. Alison Marquis,Francisco A. Sylvester,Margaret H. Collins,Suresh Venkateswaran,Marla Dubinsky,Vin Tangpricha,Krista Spada,Bradley Saul,Jessie Wang,Jose Serrano,Kevin A. Hommel,Urko M. Marigorta,Greg Gibson,Ramnik J. Xavier,Ramnik J. Xavier,Ramnik J. Xavier,Subra Kugathasan,Thomas D. Walters,Lee A. Denson +54 more
TL;DR: The findings support the utility of initial clinical activity and treatment response by 4 weeks to predict week 52 corticosteroid-free remission with mesalazine alone in children who are newly diagnosed with ulcerative colitis.
Journal ArticleDOI
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
TL;DR: A wide variety of drugs are now available for the treatment of ulcerative colitis, enabling the individualized choice of the best treatment for each patient.
Journal ArticleDOI
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
TL;DR: Current evidence on the indications, judicious use, effectiveness and safety of anti-TNF agents in paediatric IBD, specifically infliximab and adalimumab, are reviewed to provide personalized therapeutic strategies.
Journal ArticleDOI
Clinical value of fecal calprotectin.
TL;DR: The aims of this review are to provide an overview of the methods used to measure FCP and to review the evidence supporting the use of FCP in IBD, particularly as it pertains to screening, monitoring and predicting disease relapse.
Journal ArticleDOI
Probiotics for induction of remission in ulcerative colitis
Lakhbir Kaur,Morris Gordon,Patricia Anne Baines,Zipporah Iheozor-Ejiofor,Vasiliki Sinopoulou,Anthony K Akobeng +5 more
TL;DR: Probiotics did not lead to any serious adverse events in any of the seven studies that reported on it, however five adverse events were reported in the placebo arm of one study, and the certainty of the evidence was low.
References
More filters
Journal Article
Cochrane Handbook for Systematic Reviews of Interventions
Journal ArticleDOI
An obesity-associated gut microbiome with increased capacity for energy harvest
Peter J. Turnbaugh,Ruth E. Ley,Michael A. Mahowald,Vincent Magrini,Elaine R. Mardis,Jeffrey I. Gordon +5 more
TL;DR: It is demonstrated through metagenomic and biochemical analyses that changes in the relative abundance of the Bacteroidetes and Firmicutes affect the metabolic potential of the mouse gut microbiota and indicates that the obese microbiome has an increased capacity to harvest energy from the diet.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
TL;DR: It is concluded that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis.
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Related Papers (5)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Frank M. Ruemmele,Frank M. Ruemmele,Frank M. Ruemmele,Gábor Veres,Kaija-Leena Kolho,Anne Griffiths,Arie Levine,Johanna C. Escher,J. Amil Dias,Arrigo Barabino,Christian Braegger,Jiri Bronsky,Stephan Buderus,Javier Martín-de-Carpi,L. de Ridder,Ulrika L. Fagerberg,Jean-Pierre Hugot,Jaroslaw Kierkus,Sanja Kolaček,Sibylle Koletzko,Paolo Lionetti,Erasmo Miele,V.M. Navas Lopez,Anders Paerregaard,Richard K Russell,Daniela Elena Serban,Ron Shaoul,P. van Rheenen,Gigi Veereman,B Weiss,David Wilson,Axel Dignass,A Eliakim,Harland S. Winter,Dan Turner +34 more
ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents
Arie Levine,Sibylle Koletzko,Dan Turner,Johanna C. Escher,Salvatore Cucchiara,Lissy de Ridder,Kaija-Leena Kolho,Gábor Veres,Richard K Russell,Anders Paerregaard,Stephan Buderus,Mary-Louise C. Greer,Jorge Amil Dias,Gigi Veereman-Wauters,Paolo Lionetti,Malgorzata Sladek,Javier Martín de Carpi,Annamaria Staiano,Frank M. Ruemmele,David C. Wilson +19 more